Drugs / SHR-2004
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06280768 | Mar → Dec 2024 | atrial fibrillation | Beijing Suncadia Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
| Phase 1 | NCT05369767 | May 2022 → Jan 2023 | — | Beijing Suncadia Pharmaceuticals Co., Ltd | Unknown | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06220123 | Feb → Dec 2024 | — | Beijing Suncadia Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 2 | NCT05752461 | Apr 2023 → Apr 2024 | — | Beijing Suncadia Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06825416 | Mar 2025 → Feb 2026 | — | Beijing Suncadia Pharmaceuticals Co., Ltd | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-2004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06280768 ↗ |
| Modality | Monoclonal antibody | “SHR-2004 is a humanized monoclonal antibody” PMID 39166425 ↗ Aug 2024 |
| Route | Intravenous | “SHR-2004 administered either intravenously (i.v.; Part A) or subcutaneously (s.c.; Part B)” PMID 39166425 ↗ Aug 2024 |
| Route | Subcutaneous | “SHR-2004 administered either intravenously (i.v.; Part A) or subcutaneously (s.c.; Part B)” PMID 39166425 ↗ Aug 2024 |